Evidence map›Paper›PMID 33245716›Full record

ArticleOncotarget2020

Evidence for context-dependent functions of KDM5B in prostate development and prostate cancer.

Bigang Liu, Rahul Kumar, Hseuh-Ping Chao, Rashid Mehmood, Yibing Ji, Amanda Tracz, Dean G Tang

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Bigang LiuDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas M.D Anderson Cancer Center, Science Park, Smithville, TX, USA.
Rahul KumarDepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Hseuh-Ping ChaoDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas M.D Anderson Cancer Center, Science Park, Smithville, TX, USA.
Rashid MehmoodDepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Yibing JiDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas M.D Anderson Cancer Center, Science Park, Smithville, TX, USA.
Amanda TraczDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas M.D Anderson Cancer Center, Science Park, Smithville, TX, USA.
Dean G TangDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas M.D Anderson Cancer Center, Science Park, Smithville, TX, USA.
The University of Texas MD Anderson Cancer Center · USRoswell Park Comprehensive Cancer Center · USAlfaisal University · SAThe University of Texas at Austin · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa CellsR01CA240290 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 2019 to 2026
$3.1M
Tumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPCR01CA237027 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI TANG, DEAN G. · 2019 to 2023
$2.2M
Correlative efficacy, biomarker, and mechanistic studies associated with a phase Ib/II clinical trial of treating mCRPC patients with enzalutamide and VenetoclaxR21CA237939 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI TANG, DEAN G. · 2020 to 2021
$449k
Slow-cycling cells, therapy resistance and clinical implications in prostate cancerR21CA218635 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI TANG, DEAN G. · 2018 to 2019
$404k
Flow Cytometry SorterS10OD025183 · OD · ROSWELL PARK CANCER INSTITUTE CORP · PI WALLACE, PAUL K · 2018 to 2018
$318k
NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA237027NCI NIH HHS R01 CA240290NCI NIH HHS R21 CA218635NCI NIH HHS R21 CA237939NIH HHS S10 OD025183
6 · The paper itself

Abstract

Prostate cancer (PCa) is one of the leading causes of cancer-related deaths worldwide. Prostate tumorigenesis and PCa progression involve numerous genetic as well as epigenetic perturbations. Histone modification represents a fundamental epigenetic mechanism that regulates diverse cellular processes, and H3K4 methylation, one such histone modification associated with active transcription, can be reversed by dedicated histone demethylase KDM5B (JARID1B). Abnormal expression and functions of KDM5B have been implicated in several cancer types including PCa. Consistently, our bioinformatics analysis reveals that the

Indexed as

epigeneticshyperplasiaKDM5Bprostate cancerprostate development

Identifiers

PMID33245716
PMCPMC7679033
OpenAlexW3100602732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.